Podcasts about comart

Surprise release! Clive Staples Lewis was a Christian apologist, Oxford don and spanking enthusiast. The Screwtape Letters is one of his many books, an epistolary novel published serially in the (now-defunct) Anglican weekly newspaper The Guardian during the Second World War. The letters are written by Uncle Screwtape, a demon administrator in the bureaucracy of Hell, and addressed to his young nephew Wormwood, an inexperienced tempter. Screwtape offers Wormwood advice on how to lead his 'patient' away from God, so that when he dies he can serve as food for demons. Hell as a gigantic, noisy bureaucracy in which subordinates are eaten by their superiors? Lovely stuff.Joining us for this episode are friends of the show Kevin and Matt from the wonderful Art of Darkness podcast (and There Will Be Books, Matt's other podcast, also wonderful!) For more info on Lewis' spanking enthusiasms, listen to the Art of Darkness episode on C.S. Lewis (https://artofdarkpod.com/c-s-lewis-a-jack-in-the-wardrobe)!Art of Darkness: https://artofdarkpod.comArt of Darkness on X: X.com/artofdarkpodThere Will Be Books: X.com/TherewillbbooksKevin on X: X.com/kautzmaniaMatt's new book: https://shop.ingramspark.com/b/084?params=az0Zsh8Ol7BjqsK8S6M4XHoJlnrHvYZSQMjh4VUlBZL VERY IMPORTANT INFORMATIONContact: jack.bcfh@gmail.comJack has an upcoming novel called 'Audience Capture', out October 2026 through Bonfire Books!Ko-fi: https://ko-fi.com/bookclubfromhellOur Patreon: www.patreon.com/TheBookClubfromHellJack's Substack: jackbc.substack.comJoin our Discord (the best place to interact with us): discord.gg/ZMtDJ9HscrWatch us on YouTube: https://www.youtube.com/channel/UC0n7r1ZTpsUw5exoYxb4aKA/featuredX: @bookclubhell666Jack on X: @supersquat1Capitalisimo on X: @thecapitalisimoArt by moog

This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an important reminder that not all cancers are funded and researched equally, and that behind every statistic is a person trying to live a normal life.Jake has used his lifelong PR skills to turn what is a diagnosis unlike any other into a conversation about equity, resilience and a deep societal stigma. This conversation should also serve as a reminder of how patients perceive the healthcare system and that communication is key when treating patients, many of whom are vulnerable.A huge thank you to Jake for coming on the show. If you want more information, see Jake's website: https://www.theguywithstage4breastcancer.com/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this week's episode, I'm joined by author Kait Ballenger, once again, as she rounds out the Original Sinner trilogy with Beautiful Redeemer. Charlotte and Lucifer have come a long way since their fake engagement in book one - now they have to contend with the apocalypse, timeless battles between angels and demons, an absent Father, and a meddling mother. As identities are revealed and powers are discovered, Charlotte and Lucifer question their worth in the battles to come. In the midst of all this, Charlotte's connection with Death is growing but will his and Lucifer's past get in the way of her why-choose happy ending?It was great having Kait back on to talk about the conclusion of her Original Sinner trilogy. We start the conversation with a gentle reminder of what happened in books one and two, including some major spoilers, so listen at your own discretion if you haven't read Original Sinner or Wicked Believer yet! After realizing that Lucifer and her were destined by forces grander than either of them could control, Charlotte begins to realize that she is more powerful than they could have anticipated. Kait talks about how she knew their story wasn't over, the process of bringing in Death to help balance out their dynamic, and the questions that Charlotte faces when confronted with the reality that she hasn't had nearly as much freewill as she thought. I get the scoop on upcoming books, as Kait plans to extend the universe by exploring the love stories of other seven deadly sin siblings!You can buy Beautiful Redeemer now: https://bookshop.org/a/54661/9781662528903You can learn more about Kait Ballenger here: www.kaitballenger.comArt mentioned in this episode: Cabanel, Alexandre. The Fallen Angel. 1847, Musee Fabre, Montpellier, France.If you have an author, book, or topic you want to hear about on the podcast, then don't hesitate to slide into my DMs on Instagram or shoot me an email!Subscribe to my newsletter to keep up to date on the latest podcast happenings: https://in-bed-with-books.kit.com/76d11f1d51Where else to find me:IG: @inbedwithbookspodYT: https://www.youtube.com/@InBedWithBooksPodEM: inbedwithbookspodcast@gmail.com

The most dangerous thing about hard seasons isn't the uncertainty.Join MANIFEST on Skool: https://www.skool.com/sarahprout/aboutRead my Substack: https://sarahprout.substack.comART: https://sarahproutstudio.etsy.com

Heather and Matt discuss the new James Bond game 007 First Light and talk about some of their other favorite spy based video games! Check out our brand new merch at kinshipgoods.com/getplayedFollow us on social media @getplayedpodMusic by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.com For ad-free main feed episodes, our complete back catalogue including How Did This Get Played? and our Premium DLC episodes and our exclusive show Get Anime'd where we're currently watching Serial Experiments Lain go to patreon.com/getplayedJoin us on our Discord server here: https://discord.gg/getplayedWanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.comAdvertise on Get Played via Gumball.fmAll of our links can be found at linktree.com/getplayedpodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy in pancreatic cancer, and Josh does a traditional deep dive into the world of neoadjuvant chemotherapy. He highlights ESPAC-5, PREOPANC-2, and the TAPS consortium, to name a few. A complicated but overall evolving field.Studies discussed in this episode:ESPAC-4FOLFOXIRIPREOPANC-2ESPAC-5TAPS (Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Study)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Nick and Heather discuss the supernatural, Heather's trip to Japan, and what their perfect day of gaming would look like.Check out our brand new merch at kinshipgoods.com/getplayedFollow us on social media @getplayedpodMusic by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.comFor our exclusive show Get Played DLC, ad-free main feed episodes, our complete back catalogue including How Did This Get Played? episodes go to patreon.com/getplayedJoin us on our Discord server here: https://discord.gg/getplayedWanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.comAdvertise on Get Played via Gumball.fmAll of our links can be found at linktree.com/getplayedpodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. While small incremental advances have been made, the holy grail remains elusive.Today our focus is on NAPOLI-3, the use of liposomal irinotecan (NALIRIFOX), and PANOVA-3, where TTFields are used in combination with gemcitabine/abraxane. A good conversation, though the current premise is sad. Hopefully, as time moves on, this conversation will be more optimistic. Studies discussed in this episode:NAPOLI-3PANOVA-3For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

On today's episode, Josh and Michael "advance" in their ongoing GI journey, as Michael continuously insists on saying, to discuss advanced gastric and GOJ cancer. Historically, an orphan disease with a very poor prognosis, perhaps the first rays of light are beginning to shine on this difficult-to-treat cancer type. Immunotherapy has been well established as standard of care, but are there any new agents that are emerging in this space? As always, the answer to that question is "yes," and as usual, the agent in question is trastuzumab deruxtecan. Listen on for all the surprising details, even more awful puns, and a strange tangent about the difference between a "good" and "effective" dictator.Studies discussed in this episode:Checkmate 648/649Destiny-Gastric01For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, as we enter our 200th episode, Michael and Josh continue their journey through the alimentary canal, exploring the world of stomach cancer. Gastric cancer has been notoriously difficult to treat, with a thirty-year grace period of multiple trials seeking an appropriate regimen that reduces recurrences while remaining effective. This episode gives you all the answers, and just when we thought everything was settled, immunotherapy enters the fray with MATTERHORN.Studies discussed in this episode:FLOT4-AIOMATTERHORN For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Good therapeutic options for metastatic colorectal cancer are limited after the fluoropyrimidine-based options are exhausted. This week, we explore the role of trifluridine-tipiracil (Lonsurf) and bevacizumab (VEGF inhibitor), and a newish kid on the block, fruquitinib, an oral tyrosine kinase inhibitor and vascular endothelial growth factor receptor. While not perfect, they do represent later-line options for patientsStudies discussed in this episode:SUNLIGHTFRESCO-2 For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Today's episode, like several of the greatest cult classics, comes a bit earlier than anticipated. Before we wrap up our epic recap of the colorectal space, we will give you a little taster of our UGI series with a look at early oesophageal cancer, focussing on the chemotherapy backbone and whether immunotherapy has any place in this space. Spoiler alert (as always): it does.Studies discussed in this episode:ESOPECCheckmate 577For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Siobhan Thompson (Dimension 20) joins Heather, Nick and Matt to talk about her new crowdfunded film project The Greatest Treasure in the World and to discuss the 2025 adventure game Lorelei and the Laser Eyes! You can help fund the Greatest Treasure in the world at https://seedandspark.com/fund/treasurefilm?token=0207ab0b909caf0849d33053e7ac15e7530f456a5516fcdfbf1d55241e8718d7#storyCheck out our brand new merch at kinshipgoods.com/getplayedFollow us on social media @getplayedpodMusic by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.com For ad-free main feed episodes, our complete back catalogue including How Did This Get Played? and our Premium DLC episodes and our exclusive show Get Anime'd where we're currently watching Serial Experiments Lain go to patreon.com/getplayedJoin us on our Discord server here: https://discord.gg/getplayedWanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.comAdvertise on Get Played via Gumball.fmAll of our links can be found at linktree.com/getplayedpodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Metastatic Colorectal Cancer has a dearth of targetable mutations that have effective outcomes. This week, Michael and Josh see whether the wonder drug (trastruzumab deruxtecan) works in HER2-expressing colorectal cancer. Michael takes a more positive tone, with the recycling of aspirin to reduce recurrence risk for PI3K pathway cancers.Josh promised he will have the right audio this episode - thanks to our astute listener who told us last time!Studies discussed in this episode:ALASCCADestiny-CRC01For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

UPDATED WITH CORRECT AUDIOWhile Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mutations in colorectal cancer were historically prognostic; this has now shifted with targeted therapies available for both. In the context of metastatic colorectal cancer, BRAF mutations account for up to 10% of cases and are associated with significantly poorer overall survival compared with wild-type (WT) counterparts. The median overall survival in many cases of metastatic disease was under 15 months. Five years ago, there were no options, but now we see a growing list of potential therapeutic choices. Trials discussed today include BREAKWATER and CODEBREAK 300.Studies discussed in this episode:BREAKWATERCodebreak 300For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instability (dMMR) colorectal cancer, a small but meaningful cohort. This condition affects up to 15% of patients, many of whom carry germline mutations in the MLH1 and MSH2 genes, which simply means that cells can't recognise and fix spontaneous mutations. Historically, these cancers are less responsive to chemotherapy. This week, we explore two immunotherapy regimens - pembrolizumab, ipilimumab and nivolumab.Studies discussed in this episode:Checkmate 8HWKEYNOTE-177For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it more effective without increasing toxicity? This week, we explore the intensification of chemotherapy in an effort to improve overall survival. The second topic involves the use of monoclonal antibodies and targeted therapy to enhance existing regimens. Josh also conducts his characteristic deep dive, examining the evolution and application of the monoclonal antibodies cetuximab and panitumumab over the past 15 years. He aims to answer the long-standing question: does one size fit all for colorectal cancers?Studies discussed in this episode:FOLFOXIRIBeva/CetuxFIRE-3 TrialTAILOR TrialCrystalFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including Attending Physician at MSKCC, Professor of Medicine at Weill Cornell Medical College, and the Enno W. Ercklentz Chair in Genitourinary Oncology.Today, Jonathan explores metastatic urothelial cancer, discussing the current landscape and available treatment options, emphasising that a single approach may not be suitable for all patients. We also cover early bladder cancer and non-invasive muscle-invasive bladder cancer (NIMBC). For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

The DYNAMIC duo are back, with Michael climbing the "Everest" of oncology and exploring the role of CTDNA in stage two colorectal cancer. Josh has the easier job of exploring neoadjuvant immunotherapy (ipilimumab and nivolumab) in dMMR advanced colorectal cancer.Both are excellent trials, and a worthy addition to your reading list.Don't forget to check us out on YouTube if that's your thing!Studies discussed in this episode:DYNAMIC-IINICHE-2For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Sterling is so excited to share this episode featuring an interview with Vanessa J. Love - a born healer, open channel, and creator of The Wealth Codes. You're going to love hearing how this incredible woman is making the world a more magical place to be. Vanessa's details:Website - www.vanessajlove.comArt & Science of Energy Work Instagram - www.instagram.com/vanessajlove. YouTube - https://youtube.com/@themysticnomad?si=2aHAvCbzadACxYXIMentioned in the episode:Prophecy Posse Community Coven and Dance with the MusesFloorwash Workshop @ Ritualcravt SchoolSit with me at Ritualcravt by 3/13

This week, we explore early colorectal cancer. Maybe it's just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant.Studies discussed in this episode:IDEASTransMETEORTCFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.Studies discussed in this episode:MAPSCheckmate 743For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a faster rate than in the last twenty years combined.We explore tarlatamab, a bispecific delta-like ligand 3-directed T cell engager. The results show that, in the second-line setting, it improves overall survival (spoiler alert). The second study is IMforte, utilising lurbinectedin plus atezolizumab in the first-line setting for extensive-stage SCLCa. Again, a positive trial showing an improved median overall survival of 13.2 months vs 10.6 months, but does the toxicity profile trade off support this modest OS benefit? Tune in to find out!Studies discussed in this episode:ImforteDeLLphi-304For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapy before surgery, a change now saving lives and influencing worldwide protocols. As a devoted mentor and a prominent participant in Cancer Research UK's initiatives, she joins us to explore how we can personalise cancer treatment more effectively and discuss the future prospects for gastrointestinal cancer therapies. Welcome, Professor Seligmann.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive role of enforumab vedotin for muscle invasive bladder cancer.We're out of breath just listing off these trials, and if this hasn't gotten you excited, then probably nothing will! See you next week, where we interview our spectacular guest Professor Jenny Seligmann, who will bring you up to date on Michael's favourite topic, colorectal cancers!Studies:IMvigor011 (NCT04660344)KEYNOTE 905/EV-303 (NCT03924895)POTOMAC (NCT03528694)ARASAFE (NCT02799602)RC48-C016 (NCT05302284)PSMAddition (NCT04720157)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years.We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal cancer, and much more.Studies:BREAKWATERNEOADJUVANT IMMUNOTHERAPY (pMMR)STELLAR-303CHECKMATE 8HWFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzumab and FLOT in HER2-positive localised oesophageal carcinoma, and investigates the use of TKIs and the novel drug nofazinlimab for those with unresectable or metastatic hepatocellular carcinoma.A jam-packed episode that aims to over-deliver on information, laughter, and hope.2026 is going to be a big one!Studies:FORTITUDE-101MATTERHORNPHERFLOT/IKF-053NCT04669496For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

We are BACK and it's time to get excited as various changes are on the horizon including VIDEO episodes (and this time not edited by Beattie!!!). New series begins on 2nd February, have a listen and get involved. WE'VE MISSED YA!Be a legend, get on our Patreon - https://www.patreon.com/birthdaygirlshousepartyPlease subscribe, rate and review. XXXMusic by Anne Chmelewsky: https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

Speak on condition of ananonymity. SOCOA. Art points out source of news items can be blatantly fabricated from the get-go. NPR is at it again.Do not send us moneyClickhearpodcast@protonmail.comArt-piece: Did you know that the acronym AT&T has not changed in over 200 years? It still stands for American Telephone & Telegraph! When is the last time you paid your bill by dots-n-dashes?

You guys give up or are you thirsty for more?Join us as we discuss Chris Columbus' 1990 holiday staple, ‘Home Alone.' Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/Facebook:https://www.facebook.com/didyougetthatonfilm/Youtube:https://www.youtube.com/@DidYouGetThatOnFilmWebsite:https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)Hey guys! Did you know you could text us? Hey guys! Did you know you could text us?

HAPPY NEW YEAR PARTY. Boom, there it is and another boom... the guest is Tom Parry. We round up our bests and worsts from last year and make some predictions for each other. And we take a visit to Tom's esprit de l'escalier and Cam's mum's trip to Sainsburys.Be a legend, get on our Patreon - https://www.patreon.com/birthdaygirlshousepartyPlease subscribe, rate and review. XXXEdited by Emma Corsham: https://www.emmacorsham.co.ukMusic by Anne Chmelewsky: https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

The devil works hard, but this hand works harder.Join us as we discuss Rodman Flender's 1999 dark and gory teen horror comedy, ‘Idle Hands' Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/Facebook:https://www.facebook.com/didyougetthatonfilm/Youtube:https://www.youtube.com/@DidYouGetThatOnFilmWebsite:https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)Hey guys! Did you know you could text us?

S3 EP13 - Christmas Party with Jack RookeMerry Christmas one and all from the girls and their gorgeous guest Jack Rooke, who chat school nativities and cocktail sausages, and resurrect some favourite festive gamesPlease subscribe, rate and review. XXXMusic by Anne Chmelewsky:https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

Explore the latest in accessible tech for blind users with Steven Scott and Shaun Preece. From award-winning apps like Be My Eyes and Art of Fauna to Pluto TV's audio-described content, this episode blends humour, real-life experiences, and valuable app recommendations.Aira is proud to sponsor Double Tap, supporting a community that values independence, access, and real solutions for blind and low vision users. Aira is an app that gives you on-demand visual interpreting through trained professionals who can describe surroundings, read information, or guide you using your phone's camera. It also includes Access AI, a feature that provides instant image descriptions with the option to confirm details with a live visual interpreter. Aira works with major companies, airports, universities, and retailers that offer the service for free as Access Partners, and the platform is approaching ten million calls while remaining available on both iOS and Android. Steven and Shaun kick off with some festive banter before diving into their tech talk. They share a listener demo of Art of Fauna, a cosy, accessible animal puzzle game that recently earned an Apple App Store Cultural Impact Award. Lena takes us step by step through solving a word-based jigsaw puzzle using VoiceOver, highlighting how intuitive the app is for blind players. The conversation then shifts to Be My Eyes, celebrating its cultural impact win and its growing community of nearly 10 million volunteers. Steven and Shaun discuss its seamless integration with Meta smart glasses and how it empowers blind users worldwide. Later, the hosts review Pluto TV, a free streaming service adding audio-described content (currently US only), and discuss the ongoing challenges of finding and filtering AD content easily. Their chat touches on high-visibility clothing for guide dog users, the reality of UK vs Canadian winters, and why audio description is essential for equal access to entertainment.Got a favourite accessible app or a tech tip? Email us at feedback@doubletaponair.com or WhatsApp +1-613-481-0144.Relevant LinksBe My Eyes: https://www.bemyeyes.comArt of Fauna (iOS App Store): https://apps.apple.com/app/art-of-fauna/id6450713040Pluto TV: https://pluto.tv Find Double Tap online: YouTube, Double Tap Website---Follow on:YouTube: https://www.doubletaponair.com/youtubeX (formerly Twitter): https://www.doubletaponair.com/xInstagram: https://www.doubletaponair.com/instagramTikTok: https://www.doubletaponair.com/tiktokThreads: https://www.doubletaponair.com/threadsFacebook: https://www.doubletaponair.com/facebookLinkedIn: https://www.doubletaponair.com/linkedin Subscribe to the Podcast:Apple: https://www.doubletaponair.com/appleSpotify: https://www.doubletaponair.com/spotifyRSS: https://www.doubletaponair.com/podcastiHeadRadio: https://www.doubletaponair.com/iheart About Double TapHosted by the insightful duo, Steven Scott and Shaun Preece, Double Tap is a treasure trove of information for anyone who's blind or partially sighted and has a passion for tech. Steven and Shaun not only demystify tech, but they also regularly feature interviews and welcome guests from the community, fostering an interactive and engaging environment. Tune in every day of the week, and you'll discover how technology can seamlessly integrate into your life, enhancing daily tasks and experiences, even if your sight is limited. "Double Tap" is a registered trademark of Double Tap Productions Inc. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.Studies:LITESPARK-15IMPRESS-Norway trialAbstract 1510M0BNT111 (NCT04526899)Safe Stop TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Jingle bells, jingle bells, jingle all the way to our Christmas Shopping Party with comedian, actor and writer Amy Gledhill! We chat gifts that have gone wrong, Secret Santa surprises and Rose comes up with a business idea that's better than any Dragon's Den pitch we've ever seen. It's a real Christmas cracker! Be a legend, get on our Patreon - https://www.patreon.com/birthdaygirlshousepartyPlease subscribe, rate and review. XXXMusic by Anne Chmelewsky: https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

Happy Holidays! We hope you enjoy this new episode of DYGTOF- Pulse Check. This week, we are discussing Mike Flanagan projects, Welcome to Derry and upcoming prequels/ remakes/ sequels.Pulse Checks won't be our typical movie reviews, but instead us freely discussing various horror topics including our interests, recent events, updates and announcements. But don't worry, these will not be replacing our movie reviews, we have plenty of those coming soon! Brought to you by your hosts, Ruth and DP.You can follow DP and find all of his movie ratings on his letterbox: https://letterboxd.com/maybetomorrow/Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)Hey guys! Did you know you could text us?

The moment right before everything changes.

S3 EP16 - Debutante party with Lou SandersThis week the girls are joined by all-round legend Lou Sanders for a Debutante Party. Expect royal connections, dating disasters and a distinct lack of poise. Please subscribe, rate and review. XXXMusic by Anne Chmelewsky:https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.Studies:DeLLphi-303SOHO-01ALBATROSPAULIENDREAM3ROptiTROP-Lung04For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Uh ho, we've managed to get ourselves lost on a desert island! Better have a party while we're here. And who better to join us that the fabulously funny Stuart Laws. Who are we eating first? How does Cam plan on catching fish? Will we get Stuart to say poo poo? All will be revealed in this episodeBe a legend, get on our Patreon - https://www.patreon.com/birthdaygirlshousepartyPlease subscribe, rate and review. XXXMusic by Anne Chmelewsky:https://www.annechmelewsky.comArt work by Lucy Moore:https://www.lucymooreedinburgh.com

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

S3 EP5 - Roman Party with Jen BristerComedian Jen Brister joins the girls for a Roman party. Expect wine, gladiator battles and an all powerful emperorPlease subscribe, rate and review xxxMusic by Anne Chmelewsky:https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Join us for a special soiree where we keep things 'classy' and never talk about 'farts'. Featuring special guest, the one and only Tom Allen!Music by Anne Chmelewsky:https://www.annechmelewsky.comArt work by Lucy Moore: https://www.lucymooreedinburgh.com

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the management of limited-stage small cell lung cancer, which while accounting for a minority of cases, is no less interesting and potentially confusing. Studies discussed in this episode:PCI Meta AnalysisADRIATICFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Who knew anything bad could ever happen at a summer home??We're back you guys!! Just in time for spooky season. Sorry for the long hiatus. Join us as we discuss Bryan Bertino's 2008 psychological horror, ‘The Strangers.' Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/Facebook:https://www.facebook.com/didyougetthatonfilm/Youtube:https://www.youtube.com/@DidYouGetThatOnFilmWebsite:https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)Hey guys! Did you know you could text us?

Heather, Nick and Matt go back to their old ways and experience the $10 Nintendo Switch 2 user manual/museum Nintendo Switch 2 Welcome Tour. Check out our brand new merch at kinshipgoods.com/getplayedFollow us on social media @getplayedpodMusic by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.com For ad-free main feed episodes, our complete back catalogue including How Did This Get Played? and our Premium DLC episodes and our exclusive show Get Anime'd where we're currently watching Gurren Lagann go to patreon.com/getplayed Join us on our Discord server here: https://discord.gg/getplayed Wanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.com Advertise on Get Played via Gumball.fm All of our links can be found at linktree.com/getplayedpodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

To celebrate Global Accessibility Awareness Day, Mikaela and Paul recorded a special episode live at ARCtic Conference in Oulu, Finland, with a distinguished panel of accessibility champions: Rob Whitaker, Daniel Devesa Derksen-Staats and Klemens Strasse.If accessibility seems like an overwhelming subject, don't panic; we show you not just why but also give you tips on how to get started with ensuring your apps are as accessible as possible — and remember the mantra, ‘progress over perfection'!Essential links from the episode:Global Accessibility Awareness Day: https://accessibility.dayARCtic Conference: https://arcticonference.comArt of Fauna by Klemens Strasser: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596The practice of inclusive design, by Linda Dong: https://developer.apple.com/videos/play/wwdc2021/10275/Art of Fauna by Klemklem Strasser: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596Sim Daltonism: https://apps.apple.com/gb/app/sim-daltonism/id1050503579Art of Fauna by the World's Biggest Mandarin Duck Fan: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596Conferences:SwiftCraft (19–21 May): https://swiftcraft.ukConference organisers: we'd love to feature more events here on a regular basis. Get in touch with us when early bird tickets go on sale, or when you announce speakers or something else, and we'll do our best to feature you!